$PALI
PALISADE BIO, INC.

2024 Q4 Form 10-Q Financial Statement

#000095017024124664 Filed on November 12, 2024

View on sec.gov

Income Statement

Concept 2024 Q4 2024 Q3
Revenue $0.00
YoY Change
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin $1.456M
YoY Change -12.81%
% of Gross Profit
Research & Development $16.00M
YoY Change 818.48%
% of Gross Profit
Depreciation & Amortization $1.000K
YoY Change
% of Gross Profit
Operating Expenses $3.593M
YoY Change -4.9%
Operating Profit -$3.593M
YoY Change -4.9%
Interest Expense $6.000K
YoY Change -25.0%
% of Operating Profit
Other Income/Expense, Net $106.0K
YoY Change -41.76%
Pretax Income -$3.487M
YoY Change -3.14%
Income Tax
% Of Pretax Income
Net Earnings -$3.487M
YoY Change -3.03%
Net Earnings / Revenue
Basic Earnings Per Share -$2.32
Diluted Earnings Per Share -$2.32
COMMON SHARES
Basic Shares Outstanding 1.330M 1.184M
Diluted Shares Outstanding 1.500M

Balance Sheet

Concept 2024 Q4 2024 Q3
SHORT-TERM ASSETS
Cash & Short-Term Investments $8.040M
YoY Change -47.49%
Cash & Equivalents $8.000M
Short-Term Investments
Other Short-Term Assets $734.0K
YoY Change -10.49%
Inventory
Prepaid Expenses
Receivables
Other Receivables
Total Short-Term Assets $8.870M
YoY Change -45.47%
LONG-TERM ASSETS
Property, Plant & Equipment $3.000K
YoY Change -70.0%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets $324.0K
YoY Change -40.11%
Total Long-Term Assets $466.0K
YoY Change -41.82%
TOTAL ASSETS
Total Short-Term Assets $8.870M
Total Long-Term Assets $466.0K
Total Assets $9.336M
YoY Change -45.3%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $366.0K
YoY Change -61.47%
Accrued Expenses $1.509M
YoY Change 90.05%
Deferred Revenue
YoY Change
Short-Term Debt $0.00
YoY Change
Long-Term Debt Due $235.0K
YoY Change -9.62%
Total Short-Term Liabilities $2.681M
YoY Change 1.21%
LONG-TERM LIABILITIES
Long-Term Debt $0.00
YoY Change
Other Long-Term Liabilities $47.00K
YoY Change -86.18%
Total Long-Term Liabilities $47.00K
YoY Change -86.18%
TOTAL LIABILITIES
Total Short-Term Liabilities $2.681M
Total Long-Term Liabilities $47.00K
Total Liabilities $2.728M
YoY Change -8.61%
SHAREHOLDERS EQUITY
Retained Earnings $132.6M
YoY Change 11.9%
Common Stock $11.00K
YoY Change -88.04%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $6.608M
YoY Change
Total Liabilities & Shareholders Equity $9.336M
YoY Change -45.3%

Cashflow Statement

Concept 2024 Q4 2024 Q3
OPERATING ACTIVITIES
Net Income -$3.487M
YoY Change -3.03%
Depreciation, Depletion And Amortization $1.000K
YoY Change
Cash From Operating Activities -$3.133M
YoY Change 17.78%
INVESTING ACTIVITIES
Capital Expenditures $0.00
YoY Change
Acquisitions
YoY Change
Other Investing Activities
YoY Change
Cash From Investing Activities $0.00
YoY Change
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities -180.0K
YoY Change -111.46%
NET CHANGE
Cash From Operating Activities -3.133M
Cash From Investing Activities 0.000
Cash From Financing Activities -180.0K
Net Change In Cash -3.313M
YoY Change 203.94%
FREE CASH FLOW
Cash From Operating Activities -$3.133M
Capital Expenditures $0.00
Free Cash Flow -$3.133M
YoY Change 17.78%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
dei Entity Central Index Key
EntityCentralIndexKey
0001357459
dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
Q3
dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--12-31
dei Amendment Flag
AmendmentFlag
false
CY2024Q3 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2023Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
dei Document Type
DocumentType
10-Q
dei Document Quarterly Report
DocumentQuarterlyReport
true
dei Document Period End Date
DocumentPeriodEndDate
2024-09-30
dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2024
dei Document Transition Report
DocumentTransitionReport
false
dei Entity File Number
EntityFileNumber
001-33672
dei Entity Registrant Name
EntityRegistrantName
PALISADE BIO, INC.
dei Entity Incorporation State Country Code
EntityIncorporationStateCountryCode
DE
dei Entity Tax Identification Number
EntityTaxIdentificationNumber
52-2007292
dei Entity Address Address Line1
EntityAddressAddressLine1
7750 El Camino Real, Suite 2A
dei Entity Address City Or Town
EntityAddressCityOrTown
Carlsbad
dei Entity Address State Or Province
EntityAddressStateOrProvince
CA
dei Entity Address Postal Zip Code
EntityAddressPostalZipCode
92009
dei City Area Code
CityAreaCode
858
dei Local Phone Number
LocalPhoneNumber
704-4900
dei Security12b Title
Security12bTitle
Common Stock, $0.01 par value
dei Trading Symbol
TradingSymbol
PALI
dei Security Exchange Name
SecurityExchangeName
NASDAQ
dei Entity Current Reporting Status
EntityCurrentReportingStatus
Yes
dei Entity Interactive Data Current
EntityInteractiveDataCurrent
Yes
dei Entity Filer Category
EntityFilerCategory
Non-accelerated Filer
dei Entity Small Business
EntitySmallBusiness
true
dei Entity Emerging Growth Company
EntityEmergingGrowthCompany
false
dei Entity Shell Company
EntityShellCompany
false
CY2024Q4 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
1329516
CY2024Q3 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
8040000
CY2023Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
12432000
CY2024Q3 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
830000
CY2023Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
896000
CY2024Q3 us-gaap Assets Current
AssetsCurrent
8870000
CY2023Q4 us-gaap Assets Current
AssetsCurrent
13328000
CY2024Q3 us-gaap Restricted Cash Noncurrent
RestrictedCashNoncurrent
26000
CY2023Q4 us-gaap Restricted Cash Noncurrent
RestrictedCashNoncurrent
26000
CY2024Q3 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
3000
CY2023Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
10000
CY2024Q3 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
113000
CY2023Q4 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
198000
CY2024Q3 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
324000
CY2023Q4 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
490000
CY2024Q3 us-gaap Assets
Assets
9336000
CY2023Q4 us-gaap Assets
Assets
14052000
CY2024Q3 us-gaap Accounts Payable Current
AccountsPayableCurrent
366000
CY2023Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
698000
CY2024Q3 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
1509000
CY2023Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
831000
CY2024Q3 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
449000
CY2023Q4 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
778000
CY2024Q3 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
122000
CY2023Q4 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
121000
CY2024Q3 us-gaap Accrued Insurance Current
AccruedInsuranceCurrent
235000
CY2023Q4 us-gaap Accrued Insurance Current
AccruedInsuranceCurrent
158000
CY2024Q3 us-gaap Liabilities Current
LiabilitiesCurrent
2681000
CY2023Q4 us-gaap Liabilities Current
LiabilitiesCurrent
2586000
CY2024Q3 us-gaap Derivative Liabilities Noncurrent
DerivativeLiabilitiesNoncurrent
2000
CY2023Q4 us-gaap Derivative Liabilities Noncurrent
DerivativeLiabilitiesNoncurrent
2000
CY2024Q3 us-gaap Business Combination Contingent Consideration Liability Noncurrent
BusinessCombinationContingentConsiderationLiabilityNoncurrent
45000
CY2023Q4 us-gaap Business Combination Contingent Consideration Liability Noncurrent
BusinessCombinationContingentConsiderationLiabilityNoncurrent
61000
CY2024Q3 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
0
CY2023Q4 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
90000
CY2024Q3 us-gaap Liabilities
Liabilities
2728000
CY2023Q4 us-gaap Liabilities
Liabilities
2739000
CY2024Q3 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.01
CY2023Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.01
CY2024Q3 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
280000000
CY2023Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
280000000
CY2024Q3 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
1198516
CY2024Q3 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
1198516
CY2023Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
618056
CY2023Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
618056
CY2024Q3 us-gaap Common Stock Value
CommonStockValue
11000
CY2023Q4 us-gaap Common Stock Value
CommonStockValue
6000
CY2024Q3 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
139195000
CY2023Q4 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
132811000
CY2024Q3 pali Retained Earnings Accumulated Income Deficit
RetainedEarningsAccumulatedIncomeDeficit
-132600000
CY2023Q4 pali Retained Earnings Accumulated Income Deficit
RetainedEarningsAccumulatedIncomeDeficit
-121506000
CY2024Q3 us-gaap Stockholders Equity
StockholdersEquity
6608000
CY2023Q4 us-gaap Stockholders Equity
StockholdersEquity
11313000
CY2024Q3 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
9336000
CY2023Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
14052000
CY2024Q3 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
0
CY2023Q3 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
0
us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
0
us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
250000
CY2024Q3 us-gaap Research And Development Expense Excluding Acquired In Process Cost
ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost
2137000
CY2023Q3 us-gaap Research And Development Expense Excluding Acquired In Process Cost
ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost
2104000
us-gaap Research And Development Expense Excluding Acquired In Process Cost
ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost
6979000
us-gaap Research And Development Expense Excluding Acquired In Process Cost
ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost
5522000
CY2024Q3 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
1456000
CY2023Q3 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
1674000
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
4498000
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
4644000
CY2024Q3 us-gaap Operating Expenses
OperatingExpenses
3593000
CY2023Q3 us-gaap Operating Expenses
OperatingExpenses
3778000
us-gaap Operating Expenses
OperatingExpenses
11477000
us-gaap Operating Expenses
OperatingExpenses
10166000
CY2024Q3 us-gaap Operating Income Loss
OperatingIncomeLoss
-3593000
CY2023Q3 us-gaap Operating Income Loss
OperatingIncomeLoss
-3778000
us-gaap Operating Income Loss
OperatingIncomeLoss
-11477000
us-gaap Operating Income Loss
OperatingIncomeLoss
-9916000
CY2024Q3 us-gaap Interest Expense
InterestExpense
6000
CY2023Q3 us-gaap Interest Expense
InterestExpense
8000
us-gaap Interest Expense
InterestExpense
9000
us-gaap Interest Expense
InterestExpense
11000
CY2024Q3 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
112000
CY2023Q3 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
190000
us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
392000
us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
598000
CY2024Q3 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
106000
CY2023Q3 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
182000
us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
383000
us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
587000
CY2024Q3 us-gaap Net Income Loss
NetIncomeLoss
-3487000
CY2023Q3 us-gaap Net Income Loss
NetIncomeLoss
-3596000
us-gaap Net Income Loss
NetIncomeLoss
-11094000
us-gaap Net Income Loss
NetIncomeLoss
-9329000
CY2024Q3 us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-3487000
CY2023Q3 us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-3612000
us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-11094000
us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-9345000
CY2024Q3 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
1500409
CY2024Q3 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
1500409
CY2023Q3 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
489624
CY2023Q3 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
489624
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
1168277
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
1168277
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
402074
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
402074
CY2024Q3 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-2.32
CY2024Q3 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-2.32
CY2023Q3 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-7.38
CY2023Q3 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-7.38
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-9.5
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-9.5
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-23.24
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-23.24
CY2024Q2 us-gaap Stockholders Equity
StockholdersEquity
9949000
CY2024Q3 us-gaap Net Income Loss
NetIncomeLoss
-3487000
CY2024Q3 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
95000
CY2024Q3 us-gaap Stock Issued During Period Value Issued For Services
StockIssuedDuringPeriodValueIssuedForServices
51000
CY2024Q3 pali Stock Issued During Period Value Of Common Stock Upon Warrant Exercises
StockIssuedDuringPeriodValueOfCommonStockUponWarrantExercises
0
CY2024Q3 us-gaap Stockholders Equity
StockholdersEquity
6608000
CY2023Q2 us-gaap Stockholders Equity
StockholdersEquity
15800000
CY2023Q3 us-gaap Net Income Loss
NetIncomeLoss
-3596000
CY2023Q3 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
202000
CY2023Q3 us-gaap Stockholders Equity
StockholdersEquity
14082000
CY2023Q4 us-gaap Stockholders Equity
StockholdersEquity
11313000
us-gaap Net Income Loss
NetIncomeLoss
-11094000
us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
575000
us-gaap Stock Issued During Period Value Issued For Services
StockIssuedDuringPeriodValueIssuedForServices
124000
us-gaap Restricted Stock Value Shares Issued Net Of Tax Withholdings
RestrictedStockValueSharesIssuedNetOfTaxWithholdings
-25000
us-gaap Stock Issued During Period Value Employee Stock Purchase Plan
StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
11000
CY2024Q3 us-gaap Stockholders Equity
StockholdersEquity
6608000
CY2022Q4 us-gaap Stockholders Equity
StockholdersEquity
12479000
us-gaap Net Income Loss
NetIncomeLoss
-9329000
us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
439000
pali Stock Issued During Period Value Of Common Stock Upon Warrant Exercises
StockIssuedDuringPeriodValueOfCommonStockUponWarrantExercises
1350000
CY2023Q3 us-gaap Stockholders Equity
StockholdersEquity
14082000
us-gaap Net Income Loss
NetIncomeLoss
-11094000
us-gaap Net Income Loss
NetIncomeLoss
-9329000
us-gaap Depreciation
Depreciation
3000
us-gaap Depreciation
Depreciation
4000
pali Noncash Operating Lease Expense
NoncashOperatingLeaseExpense
85000
pali Noncash Operating Lease Expense
NoncashOperatingLeaseExpense
76000
pali Recurring Fair Value Measurements Of Liabilities
RecurringFairValueMeasurementsOfLiabilities
159000
pali Recurring Fair Value Measurements Of Liabilities
RecurringFairValueMeasurementsOfLiabilities
-153000
us-gaap Issuance Of Stock And Warrants For Services Or Claims
IssuanceOfStockAndWarrantsForServicesOrClaims
124000
us-gaap Issuance Of Stock And Warrants For Services Or Claims
IssuanceOfStockAndWarrantsForServicesOrClaims
0
us-gaap Gain Loss On Disposition Of Assets
GainLossOnDispositionOfAssets
-4000
us-gaap Gain Loss On Disposition Of Assets
GainLossOnDispositionOfAssets
0
us-gaap Share Based Compensation
ShareBasedCompensation
575000
us-gaap Share Based Compensation
ShareBasedCompensation
439000
us-gaap Increase Decrease In Other Operating Capital Net
IncreaseDecreaseInOtherOperatingCapitalNet
0
us-gaap Increase Decrease In Other Operating Capital Net
IncreaseDecreaseInOtherOperatingCapitalNet
108000
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
-542000
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
-596000
us-gaap Increase Decrease In Accounts Payable And Accrued Liabilities
IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
526000
us-gaap Increase Decrease In Accounts Payable And Accrued Liabilities
IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
-184000
us-gaap Increase Decrease In Employee Related Liabilities
IncreaseDecreaseInEmployeeRelatedLiabilities
-329000
us-gaap Increase Decrease In Employee Related Liabilities
IncreaseDecreaseInEmployeeRelatedLiabilities
43000
us-gaap Increase Decrease In Operating Lease Liability
IncreaseDecreaseInOperatingLeaseLiability
-89000
us-gaap Increase Decrease In Operating Lease Liability
IncreaseDecreaseInOperatingLeaseLiability
-77000
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-9812000
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-8387000
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
0
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
4000
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
0
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-4000
us-gaap Repayments Of Short Term Debt
RepaymentsOfShortTermDebt
270000
us-gaap Repayments Of Short Term Debt
RepaymentsOfShortTermDebt
290000
us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
4000000
us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
9419000
us-gaap Proceeds From Warrant Exercises
ProceedsFromWarrantExercises
2503000
us-gaap Proceeds From Warrant Exercises
ProceedsFromWarrantExercises
2758000
pali Payment Of Warrant Inducement Issuance Costs
PaymentOfWarrantInducementIssuanceCosts
343000
pali Payment Of Warrant Inducement Issuance Costs
PaymentOfWarrantInducementIssuanceCosts
0
us-gaap Payments Of Stock Issuance Costs
PaymentsOfStockIssuanceCosts
456000
us-gaap Payments Of Stock Issuance Costs
PaymentsOfStockIssuanceCosts
567000
us-gaap Proceeds From Stock Plans
ProceedsFromStockPlans
11000
us-gaap Proceeds From Stock Plans
ProceedsFromStockPlans
0
us-gaap Payments Related To Tax Withholding For Share Based Compensation
PaymentsRelatedToTaxWithholdingForShareBasedCompensation
25000
us-gaap Payments Related To Tax Withholding For Share Based Compensation
PaymentsRelatedToTaxWithholdingForShareBasedCompensation
0
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
5420000
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
11320000
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
-4392000
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
2929000
CY2023Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
12458000
CY2022Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
12409000
CY2024Q3 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
8066000
CY2023Q3 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
15338000
CY2024Q3 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
8040000
CY2023Q3 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
15312000
CY2024Q3 us-gaap Restricted Cash And Cash Equivalents
RestrictedCashAndCashEquivalents
26000
CY2023Q3 us-gaap Restricted Cash And Cash Equivalents
RestrictedCashAndCashEquivalents
26000
CY2024Q3 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
8066000
CY2023Q3 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
15338000
us-gaap Interest Paid Net
InterestPaidNet
8000
us-gaap Interest Paid Net
InterestPaidNet
10000
pali Warrant Inducement And Equity Issuance Costs Included In Accounts Payable And Accrued Liabilities
WarrantInducementAndEquityIssuanceCostsIncludedInAccountsPayableAndAccruedLiabilities
0
pali Warrant Inducement And Equity Issuance Costs Included In Accounts Payable And Accrued Liabilities
WarrantInducementAndEquityIssuanceCostsIncludedInAccountsPayableAndAccruedLiabilities
50000
pali Non Cash Impact Of Exercise Price Reset On Outstanding Warrants Related To Down Round Provisions
NonCashImpactOfExercisePriceResetOnOutstandingWarrantsRelatedToDownRoundProvisions
0
pali Non Cash Impact Of Exercise Price Reset On Outstanding Warrants Related To Down Round Provisions
NonCashImpactOfExercisePriceResetOnOutstandingWarrantsRelatedToDownRoundProvisions
16000
pali Fair Value Of Warrants Issued To Solicitation Agent
FairValueOfWarrantsIssuedToSolicitationAgent
94000
pali Fair Value Of Warrants Issued To Solicitation Agent
FairValueOfWarrantsIssuedToSolicitationAgent
0
pali Fair Value Of Warrants Issued To Placement Agent
FairValueOfWarrantsIssuedToPlacementAgent
249000
pali Fair Value Of Warrants Issued To Placement Agent
FairValueOfWarrantsIssuedToPlacementAgent
384000
pali Deferred Equity Issuance Costs Recognized As A Reduction In Additional Paid In Capital From Financing Activities
DeferredEquityIssuanceCostsRecognizedAsAReductionInAdditionalPaidInCapitalFromFinancingActivities
37000
pali Deferred Equity Issuance Costs Recognized As A Reduction In Additional Paid In Capital From Financing Activities
DeferredEquityIssuanceCostsRecognizedAsAReductionInAdditionalPaidInCapitalFromFinancingActivities
0
pali Net Proceeds From Insurance Financing Debt Included In Prepaid And Other Assets And Other Noncurrent Assets
NetProceedsFromInsuranceFinancingDebtIncludedInPrepaidAndOtherAssetsAndOtherNoncurrentAssets
347000
pali Net Proceeds From Insurance Financing Debt Included In Prepaid And Other Assets And Other Noncurrent Assets
NetProceedsFromInsuranceFinancingDebtIncludedInPrepaidAndOtherAssetsAndOtherNoncurrentAssets
461000
pali Incremental Fair Value Of Modified Or Exchanged Warrants
IncrementalFairValueOfModifiedOrExchangedWarrants
1975000
pali Incremental Fair Value Of Modified Or Exchanged Warrants
IncrementalFairValueOfModifiedOrExchangedWarrants
0
CY2024Q3 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.01
us-gaap Preferred Stock Dividend Rate Percentage
PreferredStockDividendRatePercentage
0.045
CY2024Q3 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
132600000
CY2024Q3 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
8000000
CY2024Q2 us-gaap Stockholders Equity Reverse Stock Split
StockholdersEquityReverseStockSplit
1-for-15
CY2024Q2 us-gaap Stock Issued During Period Shares Reverse Stock Splits
StockIssuedDuringPeriodSharesReverseStockSplits
15
us-gaap Use Of Estimates
UseOfEstimates
<p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Use of Estimates</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">preparation of financial statements in conformity with U.S. GAAP requires the Company to make estimates, judgments, and assumptions that impact the reported amounts of assets and liabilities and the disclosure of contingent assets and liabilities as of the date of the balance sheet, and the reported amounts of expenses during the reporting period. The most significant estimates in the Company’s condensed consolidated financial statements relate to accrued research and development expenses and its contingent consideration obligation. Although these estimates are based on the Company’s knowledge of current events and actions it may undertake in the future, actual results may materially differ from these estimates and assumptions.</span></p>
us-gaap Prior Period Reclassification Adjustment Description
PriorPeriodReclassificationAdjustmentDescription
<p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Reclassifications</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Certain prior year amounts have been reclassified to conform to the current year presentation. During the fourth quarter of 2023, the Company reclassified the fair value of the contingent consideration milestone payment obligation associated with the Giiant License Agreement (as defined below), including transaction related costs, in the amount of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">362,000</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> from In-process research and development expenses to Research and development expenses at the consolidated statement of operations, which impacted amounts previously reported for the three and nine months ended September 30, 2023.</span></p>
CY2023Q4 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
362000
CY2024Q3 us-gaap Prepaid Insurance
PrepaidInsurance
473000
CY2023Q4 us-gaap Prepaid Insurance
PrepaidInsurance
428000
CY2024Q3 pali Prepaid Expenses And Other Current Assets Other Receivables
PrepaidExpensesAndOtherCurrentAssetsOtherReceivables
96000
CY2023Q4 pali Prepaid Expenses And Other Current Assets Other Receivables
PrepaidExpensesAndOtherCurrentAssetsOtherReceivables
148000
CY2024Q3 pali Prepaid Subscriptions And Fees
PrepaidSubscriptionsAndFees
148000
CY2023Q4 pali Prepaid Subscriptions And Fees
PrepaidSubscriptionsAndFees
138000
CY2024Q3 pali Prepaid Software Licenses
PrepaidSoftwareLicenses
19000
CY2023Q4 pali Prepaid Software Licenses
PrepaidSoftwareLicenses
64000
CY2024Q3 us-gaap Deposit Assets
DepositAssets
12000
CY2023Q4 us-gaap Deposit Assets
DepositAssets
0
CY2024Q3 us-gaap Deferred Finance Costs Current Net
DeferredFinanceCostsCurrentNet
76000
CY2023Q4 us-gaap Deferred Finance Costs Current Net
DeferredFinanceCostsCurrentNet
112000
CY2024Q3 us-gaap Other Prepaid Expense Current
OtherPrepaidExpenseCurrent
6000
CY2023Q4 us-gaap Other Prepaid Expense Current
OtherPrepaidExpenseCurrent
6000
CY2024Q3 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
830000
CY2023Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
896000
pali Deferred Equity Issuance Costs
DeferredEquityIssuanceCosts
37000
CY2024Q3 us-gaap Prepaid Expense Noncurrent
PrepaidExpenseNoncurrent
324000
CY2023Q4 us-gaap Prepaid Expense Noncurrent
PrepaidExpenseNoncurrent
478000
CY2024Q3 pali Other Noncurrent Assets
OtherNoncurrentAssets
0
CY2023Q4 pali Other Noncurrent Assets
OtherNoncurrentAssets
12000
CY2024Q3 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
324000
CY2023Q4 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
490000
CY2024Q3 pali Accrued Accounts Payable
AccruedAccountsPayable
118000
CY2023Q4 pali Accrued Accounts Payable
AccruedAccountsPayable
146000
CY2024Q3 pali Accrued Clinical Trial Costs
AccruedClinicalTrialCosts
174000
CY2023Q4 pali Accrued Clinical Trial Costs
AccruedClinicalTrialCosts
20000
CY2024Q3 pali Accrued Cmc Expenses
AccruedCMCExpenses
264000
CY2023Q4 pali Accrued Cmc Expenses
AccruedCMCExpenses
5000
CY2024Q3 pali Accrued Director Stipends
AccruedDirectorStipends
59000
CY2023Q4 pali Accrued Director Stipends
AccruedDirectorStipends
106000
CY2024Q3 us-gaap Supplemental Unemployment Benefits Severance Benefits
SupplementalUnemploymentBenefitsSeveranceBenefits
0
CY2023Q4 us-gaap Supplemental Unemployment Benefits Severance Benefits
SupplementalUnemploymentBenefitsSeveranceBenefits
131000
CY2024Q3 pali Accrued Joint Development Expenses
AccruedJointDevelopmentExpenses
669000
CY2023Q4 pali Accrued Joint Development Expenses
AccruedJointDevelopmentExpenses
98000
CY2024Q3 us-gaap Business Combination Contingent Consideration Liability Current
BusinessCombinationContingentConsiderationLiabilityCurrent
0
CY2023Q4 us-gaap Business Combination Contingent Consideration Liability Current
BusinessCombinationContingentConsiderationLiabilityCurrent
143000
CY2024Q3 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
225000
CY2023Q4 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
182000
CY2024Q3 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
1509000
CY2023Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
831000
CY2024Q3 us-gaap Business Combination Contingent Consideration Liability Noncurrent
BusinessCombinationContingentConsiderationLiabilityNoncurrent
45000
CY2023Q4 us-gaap Business Combination Contingent Consideration Liability Noncurrent
BusinessCombinationContingentConsiderationLiabilityNoncurrent
61000
CY2024Q3 pali Changes In Fair Value Of Contingent Consideration
ChangesInFairValueOfContingentConsideration
164000
pali Changes In Fair Value Of Contingent Consideration
ChangesInFairValueOfContingentConsideration
159000
CY2023Q3 pali Changes In Fair Value Of Contingent Consideration
ChangesInFairValueOfContingentConsideration
0
pali Changes In Fair Value Of Contingent Consideration
ChangesInFairValueOfContingentConsideration
0
CY2024Q3 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
280000000
CY2024Q3 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.01
CY2024Q3 us-gaap Warrants And Rights Outstanding
WarrantsAndRightsOutstanding
1557470
CY2023Q4 us-gaap Warrants And Rights Outstanding
WarrantsAndRightsOutstanding
272211
CY2023Q4 pali Class Of Warrant Or Right Number Outstanding
ClassOfWarrantOrRightNumberOutstanding
272211
CY2023 pali Class Of Warrant Or Right Outstanding Weighted Average Exercise Price
ClassOfWarrantOrRightOutstandingWeightedAverageExercisePrice
144.78
CY2023 pali Class Of Warrant Or Right Outstanding Weighted Average Remaining Contractual Life
ClassOfWarrantOrRightOutstandingWeightedAverageRemainingContractualLife
P4Y1M13D
pali Class Of Warrant Or Right Issued During Period
ClassOfWarrantOrRightIssuedDuringPeriod
1731767
pali Class Of Warrant Or Right Issued During Period Weighted Average Exercise Price
ClassOfWarrantOrRightIssuedDuringPeriodWeightedAverageExercisePrice
5.13
pali Class Of Warrant Or Right Issued During Period Weighted Average Remaining Contractual Life
ClassOfWarrantOrRightIssuedDuringPeriodWeightedAverageRemainingContractualLife
P6Y6M
pali Class Of Warrant Or Right Exercised During Period
ClassOfWarrantOrRightExercisedDuringPeriod
446304
pali Class Of Warrant Or Right Exercised During Period Weighted Average Exercise Price
ClassOfWarrantOrRightExercisedDuringPeriodWeightedAverageExercisePrice
5.61
pali Class Of Warrant Or Right Forfeited Expired Or Cancelled During Period
ClassOfWarrantOrRightForfeitedExpiredOrCancelledDuringPeriod
204
pali Class Of Warrant Or Right Forfeited Expired Or Cancelled During Period Weighted Average Exercise Price
ClassOfWarrantOrRightForfeitedExpiredOrCancelledDuringPeriodWeightedAverageExercisePrice
17438.12
CY2024Q3 pali Class Of Warrant Or Right Number Outstanding
ClassOfWarrantOrRightNumberOutstanding
1557470
pali Class Of Warrant Or Right Outstanding Weighted Average Exercise Price
ClassOfWarrantOrRightOutstandingWeightedAverageExercisePrice
21.58
pali Class Of Warrant Or Right Outstanding Weighted Average Remaining Contractual Life
ClassOfWarrantOrRightOutstandingWeightedAverageRemainingContractualLife
P5Y11M23D
CY2024Q3 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
92000
CY2023Q3 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
192000
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
563000
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
429000
CY2024Q3 us-gaap Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Stock Options
EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions
300000
us-gaap Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Period For Recognition1
EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1
P1Y7M2D
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Outstanding Weighted Average Remaining Contractual Terms
ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms
P0Y8M4D
CY2024Q3 pali Accrued Joint Development Expenses
AccruedJointDevelopmentExpenses
700000
CY2023Q4 pali Accrued Joint Development Expenses
AccruedJointDevelopmentExpenses
100000
pali Collaborations And License Agreements Upfront Fee
CollaborationsAndLicenseAgreementsUpfrontFee
1000000
us-gaap Royalty Expense
RoyaltyExpense
6750000
us-gaap Revenue From Contract With Customer Including Assessed Tax
RevenueFromContractWithCustomerIncludingAssessedTax
300000
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
16000000
CY2024Q3 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
16000000
CY2024Q3 pali Class Of Warrant Or Right Number Of Rights Issued
ClassOfWarrantOrRightNumberOfRightsIssued
1
pali Contingent Value Right Pro Rata Net Proceeds From Sale Or Licensing
ContingentValueRightProRataNetProceedsFromSaleOrLicensing
0.80
us-gaap Royalty Expense
RoyaltyExpense
4500000
pali Maximum Aggregate Consideration
MaximumAggregateConsideration
5000000
pali Milestone Payments
MilestonePayments
1500000
pali Closing Period Of Merger Agreement
ClosingPeriodOfMergerAgreement
P48M
pali Proceeds Deposited Into The Cvr Escrow
ProceedsDepositedIntoTheCvrEscrow
0.20
pali Closing Period Of Merger Agreement
ClosingPeriodOfMergerAgreement
P48M
CY2022Q4 pali Collaborations And License Agreements Upfront Fee
CollaborationsAndLicenseAgreementsUpfrontFee
0
CY2024Q3 us-gaap Net Income Loss
NetIncomeLoss
-3487000
CY2023Q3 us-gaap Net Income Loss
NetIncomeLoss
-3596000
us-gaap Net Income Loss
NetIncomeLoss
-11094000
us-gaap Net Income Loss
NetIncomeLoss
-9329000
CY2024Q3 us-gaap Warrant Down Round Feature Increase Decrease In Equity Amount1
WarrantDownRoundFeatureIncreaseDecreaseInEquityAmount1
0
CY2023Q3 us-gaap Warrant Down Round Feature Increase Decrease In Equity Amount1
WarrantDownRoundFeatureIncreaseDecreaseInEquityAmount1
-16000
us-gaap Warrant Down Round Feature Increase Decrease In Equity Amount1
WarrantDownRoundFeatureIncreaseDecreaseInEquityAmount1
0
us-gaap Warrant Down Round Feature Increase Decrease In Equity Amount1
WarrantDownRoundFeatureIncreaseDecreaseInEquityAmount1
-16000
CY2024Q3 us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-3487000
CY2024Q3 us-gaap Net Income Loss Available To Common Stockholders Diluted
NetIncomeLossAvailableToCommonStockholdersDiluted
-3487000
CY2023Q3 us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-3612000
CY2023Q3 us-gaap Net Income Loss Available To Common Stockholders Diluted
NetIncomeLossAvailableToCommonStockholdersDiluted
-3612000
us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-11094000
us-gaap Net Income Loss Available To Common Stockholders Diluted
NetIncomeLossAvailableToCommonStockholdersDiluted
-11094000
us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-9345000
us-gaap Net Income Loss Available To Common Stockholders Diluted
NetIncomeLossAvailableToCommonStockholdersDiluted
-9345000
CY2024Q3 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
1500409
CY2024Q3 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
1500409
CY2023Q3 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
489624
CY2023Q3 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
489624
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
1168277
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
1168277
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
402074
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
402074
CY2024Q3 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-2.32
CY2024Q3 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-2.32
CY2023Q3 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-7.38
CY2023Q3 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-7.38
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-9.5
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-9.5
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-23.24
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-23.24
us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
1300939
us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
331220
CY2024Q3 us-gaap Lessee Operating Lease Liability Payments Remainder Of Fiscal Year
LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear
34000
CY2024Q3 us-gaap Lessee Operating Lease Liability Payments Due Next Twelve Months
LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths
94000
CY2024Q3 us-gaap Lessee Operating Lease Liability Payments Due
LesseeOperatingLeaseLiabilityPaymentsDue
128000
CY2024Q3 us-gaap Lessee Operating Lease Liability Undiscounted Excess Amount
LesseeOperatingLeaseLiabilityUndiscountedExcessAmount
6000
CY2024Q3 us-gaap Operating Lease Liability
OperatingLeaseLiability
122000
CY2024Q2 us-gaap Restructuring Reserve
RestructuringReserve
0
CY2023Q2 us-gaap Restructuring Reserve
RestructuringReserve
0
CY2023Q4 us-gaap Restructuring Reserve
RestructuringReserve
131000
CY2022Q4 us-gaap Restructuring Reserve
RestructuringReserve
180000
CY2024Q3 us-gaap Restructuring Reserve Accrual Adjustment1
RestructuringReserveAccrualAdjustment1
0
CY2023Q3 us-gaap Restructuring Reserve Accrual Adjustment1
RestructuringReserveAccrualAdjustment1
0
us-gaap Restructuring Reserve Accrual Adjustment1
RestructuringReserveAccrualAdjustment1
-3000
us-gaap Restructuring Reserve Accrual Adjustment1
RestructuringReserveAccrualAdjustment1
0
CY2024Q3 us-gaap Payments For Restructuring
PaymentsForRestructuring
0
CY2023Q3 us-gaap Payments For Restructuring
PaymentsForRestructuring
0
us-gaap Payments For Restructuring
PaymentsForRestructuring
128000
us-gaap Payments For Restructuring
PaymentsForRestructuring
180000
CY2024Q3 us-gaap Restructuring Reserve
RestructuringReserve
0
CY2023Q3 us-gaap Restructuring Reserve
RestructuringReserve
0
CY2024Q3 us-gaap Restructuring Reserve
RestructuringReserve
0
CY2023Q3 us-gaap Restructuring Reserve
RestructuringReserve
0
CY2024Q3 ecd Rule10b51 Arr Adopted Flag
Rule10b51ArrAdoptedFlag
false
CY2024Q3 ecd Non Rule10b51 Arr Adopted Flag
NonRule10b51ArrAdoptedFlag
false
CY2024Q3 ecd Rule10b51 Arr Trmntd Flag
Rule10b51ArrTrmntdFlag
false
CY2024Q3 ecd Non Rule10b51 Arr Trmntd Flag
NonRule10b51ArrTrmntdFlag
false

Files In Submission

Name View Source Status
0000950170-24-124664-index-headers.html Edgar Link pending
0000950170-24-124664-index.html Edgar Link pending
0000950170-24-124664.txt Edgar Link pending
0000950170-24-124664-xbrl.zip Edgar Link pending
Financial_Report.xlsx Edgar Link pending
MetaLinks.json Edgar Link pending
pali-20240930.htm Edgar Link pending
pali-20240930.xsd Edgar Link pending
pali-ex31_1.htm Edgar Link pending
pali-ex31_2.htm Edgar Link pending
pali-ex32_1.htm Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
FilingSummary.xml Edgar Link unprocessable
pali-20240930_htm.xml Edgar Link completed
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R38.htm Edgar Link pending
R39.htm Edgar Link pending
R4.htm Edgar Link pending
R40.htm Edgar Link pending
R41.htm Edgar Link pending
R42.htm Edgar Link pending
R43.htm Edgar Link pending
R44.htm Edgar Link pending
R5.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending